Management of Hypertension, Aortic Stenosis, and New Left Bundle‑Branch Block

Blood‑Pressure Management in Aortic Stenosis

In adults with asymptomatic aortic stenosis and hypertension, antihypertensive therapy should be initiated at low doses and titrated upward as needed (Class I, Level B). American College of Cardiology 1
The coexistence of hypertension and aortic stenosis (“two resistors in series”) markedly increases cardiovascular morbidity and mortality; therefore strict blood‑pressure control is essential (Class I, Level B). American College of Cardiology 1
Angiotensin‑renin‑system blockade (ACE‑inhibitors or ARBs such as losartan) is advantageous in aortic stenosis because it reduces left‑ventricular fibrosis, improves hypertension control, and enhances effort tolerance (Class IIa, Level B). American College of Cardiology 1
Target blood pressure should be <130/80 mm Hg to lower cardiovascular risk and slow progression of left‑ventricular hypertrophy (Class I, Level A). European Society of Cardiology 5

New‑onset LBBB accompanied by exertional fatigue signals a high likelihood of obstructive coronary artery disease and should prompt diagnostic work‑up (Class I, Level B). American Heart Association 7
Coronary computed‑tomography angiography with fractional‑flow‑reserve (FFR‑CT) is a reasonable non‑invasive first‑line test to exclude obstructive CAD in intermediate‑risk patients with new LBBB and atypical symptoms (Class IIa, Level B). American College of Cardiology 6

Beta‑blockers are appropriate for aortic‑stenosis patients who have reduced ejection fraction, prior myocardial infarction, arrhythmias, or angina (Class IIa, Level B). American College of Cardiology 1
In mild‑to‑moderate aortic stenosis with preserved ejection fraction, beta‑blockers are not contraindicated but should be introduced cautiously and titrated carefully (Class IIb, Level C). American College of Cardiology 1
A resting heart rate of 90–100 bpm may represent a compensatory mechanism in aortic stenosis; aggressive heart‑rate lowering without a clear indication is discouraged (Class IIb, Level C). American Heart Association 8
Initiating metoprolol succinate 25 mg daily for rate control is reasonable, provided close monitoring for symptoms of low cardiac output (e.g., worsening fatigue, dyspnea) (Class IIa, Level B). American College of Cardiology 6

A repeat transthoracic echocardiogram is appropriate to reassess aortic‑valve severity and left‑ventricular function when new LBBB and symptoms develop (Class I, Level B). American College of Cardiology 1
The usual 3‑year interval for routine echocardiographic surveillance is too long in the setting of new conduction abnormalities and exertional fatigue; repeat imaging should be performed within 6–12 months (Class IIa, Level C). Praxis Medical Insights 3

An LDL‑C of 54 mg/dL achieved with high‑intensity statin plus ezetimibe meets the guideline target of <70 mg/dL for patients with diabetes (Class I, Level A). Canadian Cardiovascular Society 9
Lifelong statin therapy is recommended for secondary prevention in high‑risk cardiovascular patients (Class I, Level A). Canadian Cardiovascular Society 9

Do not assume new LBBB is benign; it significantly raises the risk of cardiovascular death, heart‑failure hospitalization, and sudden death (Class I, Level B). American Heart Association 7
Avoid excessive diuresis in aortic‑stenosis patients, who are preload‑dependent; volume depletion can precipitate hypotension and low‑output states (Class I, Level B). American College of Cardiology 1
Do not aggressively lower heart rate with beta‑blockers in aortic stenosis without careful monitoring, as compensatory tachycardia may be maintaining cardiac output (Class IIb, Level C). American Heart Association 8
Do not delay repeat echocardiography when new symptoms or conduction abnormalities arise (Class I, Level B). American College of Cardiology 1